BidaskClub upgraded shares of Ocular Therapeutix (NASDAQ:OCUL) from a sell rating to a hold rating in a research report released on Tuesday morning.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Ocular Therapeutix from a hold rating to a buy rating and set a $6.50 target price on the stock in a report on Tuesday, March 13th. BTIG Research restated a buy rating on shares of Ocular Therapeutix in a report on Sunday, March 11th. HC Wainwright restated a buy rating and set a $10.00 target price on shares of Ocular Therapeutix in a report on Friday, March 9th. Cantor Fitzgerald restated a buy rating and set a $22.00 target price on shares of Ocular Therapeutix in a report on Thursday, March 8th. Finally, ValuEngine upgraded shares of Ocular Therapeutix from a strong sell rating to a sell rating in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $11.70.
Shares of Ocular Therapeutix (NASDAQ OCUL) opened at $6.99 on Tuesday. Ocular Therapeutix has a 12 month low of $3.30 and a 12 month high of $11.79. The company has a current ratio of 3.23, a quick ratio of 3.22 and a debt-to-equity ratio of 0.48.
Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.14. The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.51 million. Ocular Therapeutix had a negative net margin of 3,296.20% and a negative return on equity of 145.73%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.52) EPS. sell-side analysts forecast that Ocular Therapeutix will post -1.91 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Voya Investment Management LLC acquired a new position in Ocular Therapeutix in the 2nd quarter worth $102,000. Nationwide Fund Advisors lifted its holdings in Ocular Therapeutix by 10.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,204 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Ocular Therapeutix by 45.3% in the 2nd quarter. New York State Common Retirement Fund now owns 18,600 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 5,799 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Ocular Therapeutix by 24.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,739 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 3,650 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in Ocular Therapeutix by 148.7% in the 4th quarter. Deutsche Bank AG now owns 50,065 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 29,938 shares in the last quarter. Hedge funds and other institutional investors own 36.24% of the company’s stock.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/23/bidaskclub-upgrades-ocular-therapeutix-ocul-to-hold.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.